Laser Tissue Welding, Inc. is a privately owned biotherapeutic company located in Humble Texas, incorporated in Delaware in 2004. It is structured as a vertically integrated research, development, and manufacturing entity. At present the company focuses its research and product development on two patented and proprietary platforms:

 
  • Transparent bio-absorbable human albumin burns and chronic wound dressings that can be customized with growth factors and antibiotics.
 

Laser Tissue Welding will transform the operative surgery landscape by providing accurate sutureless surgical repair and hemostasis that enhances patient outcomes by simplifying surgery in areas of unmet clinical need.

 

It is an elegant disruptive and futuristic combination device which consists of an 810nm diode laser and two human albumin based biomaterials. Special areas of unmet clinical need addressed by this combination device are surgical interventions on solid visceral organs such as the liver and kidney involved in trauma, cancer and transplantation; and patients requiring low pressure surgical hemostasis while therapeutically anticoagulated or having hemodilutional/hypothermic coagulation failure. The benefits of this new paradigm are due to its ability to quickly repair and control hemorrhage, bile or urine with minimal thermal injury. These benefits include a decrease in operating time, ability to control bleeding instantly, decrease in morbidity and mortality, shorter hospital stay, decrease in healthcare costs; conservation of blood products by reducing transfusion requirements; and increase the donor pool for liver transplantation by enabling split liver transplantation. 

 

The company has one issued patent; two patents are pending and have exclusive rights via a licensing agreement to the technology. Laser Tissue Welding has completed development of a clinical device and has successfully completed a human feasibility clinical study in 2012.

Grants and Awards:
2006-2007: Phase I Small Business Innovative Research (SBIR) Commercialization Grant award-National Institutes of Health.
2007-2008: Texas Emerging Technology Fund (TETF) awarded a research matching grant from the office of the Governor. 
2009-2010: Qualifying Therapeutic Discovery Project Grant (QTDP) 
2010-2012: Phase II Small Business Innovative Research (SBIR) Commercialization Grant award- National Institutes of Health.  (Hepatectomy application)

2012-2015: Fast Track SBIR Grant Award (Laparoscopic Nephrectomy application)


Disclosure: *The US Food and Drug Administration (FDA) has not approved the Laser Tissue Welding System for general use.




Latest News
Recent Articles
4/8/2012 6:36:51 AM
November 15, 2008: The Business Makers Interview
Episode 180: Flashback— Yasmin Wadia, Laser Tissue Welding Inc.
Russ Capper reports in from the Houston Technology Showcase with a discussion with Dr. Yasmin Wadia, inventor of a laser tissue welding device, a “point and shoot” process that fuses tissue and stops bleeding immediately. This sutureless process could change the future of surgery and recovery. Click to navigate
4/7/2012 10:18:14 AM
Dr. Yasmin Wadia honored as 'Woman Entrepreneur of the Year'
Four prominent Indian Americans were honoured for their entrepreneurship and community services by the Indo American Chamber of Commerce of Greater Houston (IACCGH).
The Hindu
NDTV.com
RMR Media - You Tube - 7.17' to 7.30'

4/7/2012 10:09:11 AM
06/20/2011: Companies To Watch: Larta NIH-CAP 2010/11 Participant Laser Tissue Welding

Larta NIH-CAP 2010/11 Participant Laser Tissue Welding

Laser Tissue Welding (LTW), a current NIH Commercialization Assistant Program participant (NIH-CAP), is a privately owned biotherapeutic medical device company located in Humble Texas, and was founded and incorporated in Delaware in 2004. LTW’s innovation is a new paradigm in surgical care, an enabling combination surgical device that seals hemorrhage and fluid leaks accurately, instantly on demand without burning. The technology uses a diode laser and two human serum albumin biodegradable bio-materials to enable surgical interventions on vascular solid visceral organs as the liver, kidney and spleen and hemostasis in coagulopathic patients requiring surgery..Read more

LARTA VOX

11/20/2008 12:00:00 AM
Podcast: LTW Texas Life Sciences Conference Presentation
The Thursday Commercialization Forum showcased promising technologies from research institutions, a number of Texas’ most innovative and exciting life science companies, including finalist start-ups from the Emerging Technology Fund. Click to download.

 
login